Pruritus

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Monoclonal antibody 1 substance
Phase III: 1 Phase II/III: 1 Phase I (Other): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    DUPILUMAB
    2023-508879-36-00 6 countries 2022 n=172
    Recruiting

Phase II/III

1 trial
  • Cara Therapeutics Inc. Commercial
    DIFELIKEFALIN
    2023-503957-36-00 3 countries 2023 n=193
    Ended

Phase I (Other)

1 trial
  • Teva Branded Pharmaceutical Products R&D LLC Commercial
    IMP not specified
    2023-507018-29-00 1 country 2024 n=48
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Cara Therapeutics Inc. Commercial 1 Phase II/III 0
Teva Branded Pharmaceutical Products R&D LLC Commercial 1 Phase I (Other) 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 1
New trials by year
2022
1
2023
1
2024
1
← All indication landscapes